The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
JP Morgan approaches.
Four months after yielding first-in-human data INCA33890 enters phase 3.
But Tevimbra’s role looks shaky as adverse events loom.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
